Pmv Pharmaceuticals Inc
PMVP · NASDAQ · Healthcare / Biotechnology
1.27USD+0.06 (+4.96%)
Price History
Full chartMarket Stats
Previous Close1.21
Open1.22
Day Range1.19 – 1.27
52-Week Range1.02 – 1.88
Volume290.75K
Market Cap72.70M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.45
Dividend Yield0.00%
Beta1.37
50-Day Avg1.29
200-Day Avg1.28
About
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEODr. David H. Mack Ph.D.
- Employees54
- Headquarters400 Alexander Park Drive, Princeton, NJ, United States, 08540, USA
- Websitehttps://www.pmvpharma.com
Leadership
- Dr. David H. Mack Ph.D.Co-Founder, CEO, President & Director · b. 1962
- Dr. Arnold J. Levine Ph.D.Co-Founder, Independent Director & Member of Scientific Advisory Board · b. 1940
- Mr. Robert Ticktin J.D.General Counsel, COO & Company Secretary · b. 1962
- Dr. Deepika Jalota Pharm.D.Chief Development Officer · b. 1977
- Mr. Michael CarulliChief Financial Officer · b. 1974
- Mr. Tim Smith M.B.A.Senior VP and Head of Corporate Development & Investor Relations
- Ms. Crystal ZuckermanVice President of Human Resources
- Dr. Binh Vu Ph.D.Senior Vice President of Drug Discovery & CMC
- Dr. Marc Fellous M.D.Senior VP and Head of Clinical Development & Medical Affairs
- Ms. Laura De LeonVP & Head of Clinical Development Operations
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Market Cap72.70M
Enterprise Value-5.44M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.03
EPS-1.45
Book Value1.34
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-79.54M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-70.93%
Return on Assets-42.39%
Shares Outstanding53.46M
Shares Float43.29M
Beta1.37
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%
Analyst Ratings
Strong Buy
Based on 5 analystsTarget 4.20
- Strong Buy4
- Buy1
Ownership Breakdown
- Institutions
- 46.43%
- Insiders
- 2.37%
- Retail / Other
- 51.20%
Top Institutional Holders
- BML Capital Management LLC5.33M9.99%
- TANG CAPITAL MANAGEMENT LLC4.25M7.96%
- Sio Capital Management, LLC2.63M4.94%
- Euclidean Capital LLC2.63M4.93%
- Adage Capital Partners Gp LLC2.36M4.43%
- Acadian Asset Management LLC2.22M4.15%
- Vanguard Capital Management, LLC1.97M3.70%
- ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.96M3.67%
- Two Sigma Investments LLC1.95M3.66%
- Eversept Partners, LP1.89M3.55%
- BlackRock Inc874.37K1.64%
- Morgan Stanley - Brokerage Accounts864.31K1.62%
- Stonepine Capital Management Llc708.10K1.33%
- Longaeva Partners L.P.552.03K1.04%
- Geode Capital Management, LLC495.92K0.93%
- Aldebaran Capital LLC473.36K0.89%
- Marshall Wace Asset Management Ltd434.09K0.81%
- Bridgeway Capital Management, LLC428.85K0.80%
Top Fund Holders
- Vanguard MStar Total Stk Mkt Idx Invest1.49M2.79%
- Meridian Small Cap Growth Legacy1.06M1.98%